{
  "url": "https://seekingalpha.com/article/4813790-repligen-corporation-still-navigating-through-the-covid-cliff",
  "authorsByline": "Bret Jensen",
  "articleId": "1fd3b090d91b4a708309b7159c39e89b",
  "source": {
    "domain": "seekingalpha.com",
    "location": {
      "country": "us",
      "state": "NY",
      "city": "New York",
      "coordinates": {
        "lat": 40.7127281,
        "lon": -74.0060152
      }
    }
  },
  "imageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395657542/image_1395657542.jpg?io=getty-c-w1536",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-14T19:24:05+00:00",
  "addDate": "2025-08-14T19:36:27.368035+00:00",
  "refreshDate": "2025-08-14T19:36:27.368037+00:00",
  "score": 1.0,
  "title": "Repligen Corporation: Still Navigating Through The Covid Cliff (NASDAQ:RGEN)",
  "description": "Repligen Corporation exceeds Q2 revenue expectations with consumables & biopharma growth. Click to see RGEN's diversification strategy & post-Covid challenges.",
  "content": "Live Chat on The Biotech Forum has been dominated by discussion of covered call opportunities in recent quarters. To see what I and the other season biotech investors are targeting as trading ideas real-time, just initiate your free trial into The Biotech Forum by clicking HERE .\n\nToday, I am putting life sciences concern Repligen Corporation ( NASDAQ: RGEN ) in the spotlight. The company posted mixed second quarter results in late July, but management did bump up their FY2025 guidance. The stock has\n\nBret leads the investing group The Biotech Forum , in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More .\n\nAnalyst\u2019s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.\n\nSeeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.",
  "medium": "Article",
  "links": [],
  "labels": [
    {
      "name": "Opinion"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Seeking Alpha",
      "weight": 0.08323957
    },
    {
      "name": "life sciences concern Repligen Corporation",
      "weight": 0.08059045
    },
    {
      "name": "individual investors",
      "weight": 0.08034615
    },
    {
      "name": "mixed second quarter results",
      "weight": 0.07898912
    },
    {
      "name": "US investment adviser",
      "weight": 0.076801844
    },
    {
      "name": "Repligen Corporation",
      "weight": 0.0718755
    },
    {
      "name": "investment bank",
      "weight": 0.07051391
    },
    {
      "name": "similar derivative position",
      "weight": 0.06856803
    },
    {
      "name": "trade ideas",
      "weight": 0.06790019
    },
    {
      "name": "trading ideas",
      "weight": 0.06650322
    }
  ],
  "topics": [
    {
      "name": "Markets"
    },
    {
      "name": "Stocks"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.98291015625
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.96875
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.9658203125
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.85595703125
    }
  ],
  "sentiment": {
    "positive": 0.19373617,
    "negative": 0.15628067,
    "neutral": 0.64998317
  },
  "summary": "Life sciences company Repligen Corporation (NASDAQ:RGEN) has been under the microscope following mixed second quarter results. The company has raised its FY2025 guidance and is now focusing on its future in the market. The Biotech Forum, led by Bret Steep, offers a model portfolio with high-profile biotech stocks and weekly research and option trades.",
  "shortSummary": "Despite mixed second quarter results and potential covered call opportunities, shares of life sciences concern Repligen Corporation are volatile as they navigate the uncertain future.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "74d70d570eb8408c9324553f5e76996f",
  "places": [],
  "scraped_sources": [],
  "argos_summary": "The Biotech Forum has been focusing on covered call opportunities, with Repligen Corporation (NASDAQ: RGEN) highlighted for its mixed second quarter results but an increase in FY2025 guidance. The forum offers a model portfolio of high-upside biotech stocks and provides live discussions on trading ideas. The article emphasizes that past performance does not guarantee future results and clarifies the author's lack of investment in the mentioned companies.",
  "argos_id": "5KRWCK58Q"
}